Bavarian Nordic reports promising test results of breast cancer vaccine  

2006.11.03
The Danish biopharmaceutical company's subsidiary in California, BN ImmunoTherapeutics, has presented excellent results from preclinical tests of a breast cancer vaccine, MVA-BN-HER2
Danish biopharmaceutical company Bavarian Nordic's subsidiary in California, BN ImmunoTherapeutics, has presented excellent results from preclinical tests of a breast cancer vaccine, MVA-BN-HER2. The study showed exceptional efficacy, both in terms of inducing broad immunity as well as anti-tumour activity, writes Bavarian Nordic in a press release.
 
Peter Wulff, president and CEO of Bavarian Nordic comments: "With these promising results based on our patented MVA-BN technology, we have taken our first important step towards clinical trials with our cancer vaccines which we expect to be one of the company's cornerstones in the future." The results will be included in BN ImmunoTherapeutics' current filing for an Investigational New Drug application with the US Food and Drug Administration.
 
Bavarian Nordic has operations in Denmark, Germany, the US and Singapore. The company's patented MVA-BN technology is one of the world's safest, multivalent vaccine vectors for development of vaccines against infectious diseases (smallpox and HIV) and cancer. Bavarian Nordic has ongoing development contracts with the US government to develop Imvamune as a safe third-generation smallpox vaccine. Collaboration partners include GlaxoSmithKline, Pharmexa, Impfstoffwerk Dessau-Tornau and Vaccine Solutions.
 
Link > Bavarian Nordic  

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×